SkinHealth Systems Inc. (Class A) (SKIN) carries a Roarable Rating of E (Strong Sell) with 32/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.
As of 2026-11-03, SkinHealth Systems Inc. (Class A) (NASDAQ: SKIN) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 32/100 at a spot price of $10.38 (+4.43% 1D, market cap $64.7M). Pillar breakdown: Fundamental Cash Engine 8/20, Institutional 13F & Options Flow 3/20, SEC Balance-Sheet Forensics 8/20, FRED Macro Regime Fit 8/20, and Executive Insider Alignment 5/20. Across 1015 tracked Health Care issuers, SKIN ranks #725 in composite RQD confidence.
Within the Health Care sector (Medical/Dental Instruments), SKIN carries a Roarable E (32/100 RQD), trailing P/E of N/A, gross margin of 65.3%, and ROIC of -26.9%. By comparison, QTEX (QTREX Quantum Ltd.) holds a D- grade (36/100 RQD, P/E N/A, ROIC -35.0%, cap $68.3M) and LNSR (LENSAR Inc.) posts a E grade (18/100 RQD, P/E N/A, ROIC -35.0%, cap $71.7M). Among the 5-stock peer group, SKIN leads on earnings multiple (N/A) while MBOT leads on capital efficiency (-15.8% ROIC).
Per SKIN's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001818093), SkinHealth Systems Inc. (Class A) generated $300.8M in revenue (-10.0% YoY), -$9.5M in net income, and $37.2M in free cash flow against $499.8M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
SEC XBRL FY 2025 (10-K): 12.4% FCF Margin ($37.2M FCF) & 65.3% Gross Margin
Altman Z-Score 0.20 (DISTRESS RISK (<1.8)) • Piotroski F-Score 6/9
Put hedging (50% put share) caps near-term gamma upside (-16 pts vs max)
While SKIN currently carries a cautious 32/100 (E) rating due to Whale & Options Positioning (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.
Established market leader in Health Care with deep daily trading liquidity.
Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($12.42) and Max Pain ($10.90) forces dealer call-delta covering toward $34.55.
Forensic Repair Trigger: Halting share dilution (Disciplined Float (+0.72% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.
SkinHealth Systems Inc. (Class A) (SKIN) surged +4.43% to $10.38, trading at 29% of its 52-week range ($1.24 – $32.9). Stretched risk/reward at current multiples (-27% return on capital) under elevated 10-year interest-rate pressure.
Yahoo Finance report covering SkinHealth Systems Inc. (Class A) (SKIN) market action, institutional positioning, and fundamental catalysts.
Yahoo Finance report covering SkinHealth Systems Inc. (Class A) (SKIN) market action, institutional positioning, and fundamental catalysts.
Quiver Quantitative report covering SkinHealth Systems Inc. (Class A) (SKIN) market action, institutional positioning, and fundamental catalysts.
Investing.com UK report covering SkinHealth Systems Inc. (Class A) (SKIN) market action, institutional positioning, and fundamental catalysts.
Yahoo Finance report covering SkinHealth Systems Inc. (Class A) (SKIN) market action, institutional positioning, and fundamental catalysts.
Quiver Quantitative report covering SkinHealth Systems Inc. (Class A) (SKIN) market action, institutional positioning, and fundamental catalysts.
Pluang report covering SkinHealth Systems Inc. (Class A) (SKIN) market action, institutional positioning, and fundamental catalysts.
Yahoo Finance report covering SkinHealth Systems Inc. (Class A) (SKIN) market action, institutional positioning, and fundamental catalysts.
LONG BEACH, Calif., Oct. 22, 2026 (GLOBE NEWSWIRE) -- SkinHealth Systems Inc. (NASDAQ: SKIN), a global medical aesthetics company and home to flagship brand Hydrafacial, today announced it will report third quarter 2026
Beauty Health (NASDAQ:SKIN) released second-quarter financial results and hosted an earnings call on Thursday. Read the complete transcript below. This transcript is brought to you by Benzinga APIs. For real-time access
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
vs. -10.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
No active Ellis Vennor swing setup published on SKIN today. View full Setup Ledger →
No direct multi-tier Butterfly edges indexed yet for SKIN. Explore sector supply chains on /butterfly.
Across 1015 tracked Health Care securities in the Roarable RQD universe, SkinHealth Systems Inc. (Class A) (SKIN) ranks #725 by composite RQD confidence (32/100, grade E) and #708 by equity capitalization ($64.7M). Within this direct 5-issuer industry benchmark cohort, SKIN leads on earnings valuation at N/A trailing P/E, while MBOT leads on capital efficiency and profitability with -15.8% ROIC and — gross margin. DXR currently holds the highest overall quantitative score in the immediate peer group at 47/100 (D) compared with SKIN at 32/100 (E).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| SKIN
ACTIVE
SkinHealth Systems Inc. (Class A) | E | 32/100 | — | 65.3% | -26.9% | +4.43% | $64.7M | Benchmark Subject |
| QTEX QTREX Quantum Ltd. | D- | 36/100 | — | 0.7% | -35.0% | -8.20% | $68.3M | /qtex-vs-skin → |
| LNSR LENSAR Inc. | E | 18/100 | — | 39.4% | -35.0% | -2.91% | $71.7M | /lnsr-vs-skin → |
| MBOT Microbot Medical Inc. | E | 29/100 | — | — | -15.8% | -4.59% | $73.2M | /mbot-vs-skin → |
| DXR Daxor Corporation | D | 47/100 | — | — | — | -2.17% | $53.7M | /dxr-vs-skin → |
In its most recent audited fiscal period (FY2025, filed 2025-12-31), SkinHealth Systems Inc. (Class A) (SKIN) reported GAAP revenue of $300.8M (-10.0% vs. FY2024 revenue of $334.3M , and -24.4% cumulative change since FY2023) , GAAP net income of -$9.5M, operating cash flow of $37.5M, and free cash flow of $37.2M (+141.8% YoY). On the balance sheet, SKIN closed FY2025 with $499.8M in total assets against $0 in total debt (Altman Z-Score: 0.20, Piotroski F-Score: 6/9).
| Fiscal Period | Filing Date | Revenue | Net Income | Operating Cash Flow | Free Cash Flow | Total Assets | Total Debt |
|---|---|---|---|---|---|---|---|
| FY2025 (FY) | 2025-12-31 | $300.8M | -$9.5M | $37.5M | $37.2M | $499.8M | — |
| FY2024 (FY) | 2024-12-31 | $334.3M | -$29.1M | $16.1M | $15.4M | $685.7M | — |
| FY2023 (FY) | 2023-12-31 | $398.0M | -$100.1M | $21.8M | $21.8M | — | — |
As of 2026-11-03, SkinHealth Systems Inc. (Class A) (NASDAQ: SKIN) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 32/100 at a spot price of $10.38 (+4.43% 1D, market cap $64.7M). Pillar breakdown: Fundamental Cash Engine 8/20, Institutional 13F & Options Flow 3/20, SEC Balance-Sheet Forensics 8/20, FRED Macro Regime Fit 8/20, and Executive Insider Alignment 5/20. Across 1015 tracked Health Care issuers, SKIN ranks #725 in composite RQD confidence.
Within the Health Care sector (Medical/Dental Instruments), SKIN carries a Roarable E (32/100 RQD), trailing P/E of N/A, gross margin of 65.3%, and ROIC of -26.9%. By comparison, QTEX (QTREX Quantum Ltd.) holds a D- grade (36/100 RQD, P/E N/A, ROIC -35.0%, cap $68.3M) and LNSR (LENSAR Inc.) posts a E grade (18/100 RQD, P/E N/A, ROIC -35.0%, cap $71.7M). Among the 5-stock peer group, SKIN leads on earnings multiple (N/A) while MBOT leads on capital efficiency (-15.8% ROIC).
Per SKIN's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001818093), SkinHealth Systems Inc. (Class A) generated $300.8M in revenue (-10.0% YoY), -$9.5M in net income, and $37.2M in free cash flow against $499.8M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.
SKIN last traded at $10.38 (+4.43% on volume of 43,642 shares), positioning the stock -16.43% below its 50-day simple moving average ($12.42) and -37.51% below its 200-day simple moving average ($16.61). Across its 52-week range of $1.24 to $32.90, SKIN sits at the 28.9% percentile with a 14-day RSI of 35.8 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($9.08 to $11.68).
SkinHealth Systems Inc. (Class A) (SKIN) earns a live Roarable RQD composite score of 32/100, corresponding to a E letter grade (Roarable Strong Sell) at a spot price of $10.38 (+4.43% 1D, market capitalization $64.7M).
. (Class A) is a NASDAQ-listed issuer in the Health Care sector, within the Medical/Dental Instruments industry..1B. Per the market data, gross margin is 65.3%, indicating a high gross-profit share of revenue before operating costs.
In its latest audited SEC EDGAR 10-K filing for FY2025 (filed 2025-12-31), SkinHealth Systems Inc. (Class A) (SKIN) reported $300.8M in annual revenue (up from $334.3M in FY2024, -10.0% YoY) and -$9.5M in GAAP net income. Over the multi-year SEC filing window from FY2023 ($398.0M revenue, -$100.1M net income) through FY2025, SKIN scaled operating cash flow to $37.5M and free cash flow to $37.2M, backed by $499.8M in total assets against $0 in total debt.
No upstream or downstream links are recorded, and no proprietary signals are listed. Second-order ripples therefore cannot be traced from the provided data. A prospective investor should note that the reverse split and Nasdaq compliance activity are the principal non-financial events in the feed, and that the Q3 2026 results call is the next scheduled informational event.
Real-time company headlines, analyst actions, and sector developments for SkinHealth Systems Inc. (Class A) (SKIN) • Click "Debate This Headline" to argue it in the Roar Pit below
Yahoo Finance report covering SkinHealth Systems Inc. (Class A) (SKIN) market action, institutional positioning, and fundamental catalysts.
Yahoo Finance report covering SkinHealth Systems Inc. (Class A) (SKIN) market action, institutional positioning, and fundamental catalysts.
Quiver Quantitative report covering SkinHealth Systems Inc. (Class A) (SKIN) market action, institutional positioning, and fundamental catalysts.
Investing.com UK report covering SkinHealth Systems Inc. (Class A) (SKIN) market action, institutional positioning, and fundamental catalysts.
Yahoo Finance report covering SkinHealth Systems Inc. (Class A) (SKIN) market action, institutional positioning, and fundamental catalysts.
Quiver Quantitative report covering SkinHealth Systems Inc. (Class A) (SKIN) market action, institutional positioning, and fundamental catalysts.
Pluang report covering SkinHealth Systems Inc. (Class A) (SKIN) market action, institutional positioning, and fundamental catalysts.
Yahoo Finance report covering SkinHealth Systems Inc. (Class A) (SKIN) market action, institutional positioning, and fundamental catalysts.
Long SKIN at $9.94 targeting $13.12. Reported FCF stayed positive at $37.2M in FY 2025 while operating losses narrowed to -$20.8M from -$130.9M in FY 2023.. Institutional whale score is 3/20 and the risk/reward vs. the $1.80 52-week low is skewed heavily in favor of bulls.
@QuantViper Agree on the RQD 32/100 quality, though with 1.0 beta I'm scaling in with half-size at $9.94 and keeping dry powder in case we test $9.24.
Sitting on the sidelines or leaning short SKIN above $9.94. An Altman Z-Score of 0.2 and ROIC of -26.9% signal a fragile balance sheet and negative returns on invested capital.. Until Fundamental Cash Engine (8/20) and FCF yield (0.0%) inflect higher, upside is capped near $32.90.
To protect compute speed and zero-delay Cboe BZX data quality for active members, our current $9.95/month Roarable Pro cohort is 100% full. Join the priority waiting list below and we will notify you the moment the next batch of Pro accounts opens (and lock in your $9.95/mo rate).
Link your personal ChatGPT, Claude Desktop, or Cursor via Roarable's Model Context Protocol (`mcp.roarable.com`) to query all 5,289 stocks, inspect Butterfly supply chains, and trade your `$100K Arena` account.
Interrogate SEC 10-K/10-Q filings on demand and ask custom ticker, valuation, or short-thesis questions directly to any of our 8 specialized AI Quant Analysts.
Command our AI agents to sort and sift 5,289 stocks by custom formulas, follow multi-indicator technical & cash-flow setups, and send you instant Email/SMS breakout & downgrade alerts.
Unlock sub-second Cboe BZX streaming quotes, pre-market/after-hours delta scanners, instant SEC Form 4 insider cluster alerts, and unlimited portfolio stress-testing.
All 8 Roarable Analysts (Mara Quenwick, Gideon Ashmere, Ellis Vennor, Tessa Rookmere, Soren Halewick, Iona Brackenford, Nadia Vellacrest, and Felix Orven) are proprietary AI Quant Analysts and automated algorithmic specialists — not human financial advisors, fiduciaries, or registered broker-dealers. While one-to-many daily stock ratings and briefings are free, custom 1-on-1 Q&A, custom AI sifting/indicator alert agents, and personal ChatGPT/Claude MCP connections consume dedicated per-user compute and require a $9.95/month Roarable Pro membership. All AI outputs are for educational and research purposes only and never constitute individualized investment advice.
Enter your first name and email address below for instant 1-step account activation, daily A–E stock rating alerts, and immediate access to your $100,000.00 Virtual Cash Arena account (100% free — no credit card required).
Your $100,000 Virtual Cash Trading Account is active! Add your mobile number below if you want our #1 Weekly Quant Top Pick plus urgent breaking market alerts & SEC Form 4 CEO cluster-buy flashes sent straight to your phone: